GlassScriptPhysician profile
Noel B Salem
NPI 1982645065
$9,403.60
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,981 · 2020: $1,111 · 2021: $384 · 2022: $337 · 2023: $968 · 2024: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.51 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $4,770.55 | 2019 | |
| Amgen INC. | $1,526.78 | 2019-2024 | Enbrel, Tavneos, Krystexxa |
| Janssen Biotech, INC. | $672.74 | 2019-2024 | Tremfya, Simponi Aria |
| Abbvie INC. | $378.54 | 2019-2024 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $354.55 | 2019-2024 | |
| Ucb, INC. | $276.49 | 2019-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $188.69 | 2019-2024 | Orencia |
| Pfizer INC. | $173.41 | 2019-2023 | |
| Genentech USA, INC. | $171.78 | 2019 | |
| Lilly USA, LLC | $161.98 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $154.84 | 2021-2024 | |
| Glaxosmithkline, LLC. | $108.84 | 2019-2024 | Benlysta |
| Fresenius Kabi USA, LLC | $79.13 | 2023-2024 | Idacio |
| Mallinckrodt Enterprises LLC | $77.85 | 2019 | |
| Genzyme Corporation | $57.55 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $45.70 | 2023 | Teriparatide |
| Genentech, INC. | $38.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.24 | 2023-2024 | Opsumit |
| Organon LLC | $30.90 | 2023-2024 | Hadlima |
| Alexion Pharmaceuticals, INC. | $16.65 | 2023 | Strensiq |
| Kyowa Kirin, INC. | $15.59 | 2023 | |
| Sandoz INC. | $15.29 | 2023 | Hyrimoz |
| Octapharma USA, INC. | $14.83 | 2022 | |
| Horizon Therapeutics Plc | $13.89 | 2019 | |
| Aurinia Pharma U.S., INC. | $13.86 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.93 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.